Please Wait.....
Report
Human Recombinant DNA: Global Markets
Market Research Report I 2022-07-21 I 84 Pages I BCC Research
Description
Report Scope:
This report highlights the current and future market potential for human recombinant DNA and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, trends and key players in the market. The report also provides market projections from 2022 through 2027. An in-depth discussion of strategic alliances, industry structures, competitive dynamics, and market forces are also provided.
Report Includes:
- 24 data tables and 8 additional tables
- An overview of the global market for human recombinant DNA
- Estimation of the market size and analyses of global market trends, with data from 2020, 2021 with projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the market potential for human recombinant DNA, based on product, application, and region
- Coverage of history and future of human recombinant DNA, and latest technological advancements of the industry
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
- Coverage of regulatory landscape, product recalls, pipeline products, and discussion on future perspective, strategies, and developments of the industry
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and a relevant patent analysis
- Company profiles of major players within the industry AbbVie Inc., Amgen Inc., Eli Lilly, Sanofi
Executive Summary
Summary:
Recombinant DNA technology (RDT) is essential for improving health conditions, primarily by developing new vaccines and pharmaceuticals. The treatment strategies are improved by developing diagnostics kits, monitoring devices and new therapeutic approaches. Additionally, many other industries such as agriculture are benefiting from the research conducted on genetically modified organisms (GMO), for example microorganisms that are considered clean fuel producers and bio degraders.
Advances in oncology research for discovering underlying molecular mechanisms of cancerous cells to develop novel therapeutics is benefitting the market. The rising number of advanced cancer cases worldwide has significantly increased the need for developing DNA damage-response drugs. These drugs can improve cancer survival by providing a selective and well-tolerated treatment approach.
During the forecast period, the increasing cancer incidence is expected to drive growth in the global human recombinant DNA market. According to the REDACTED report of the World Cancer Research Fund International, breast cancer caused the second-highest number of new cancer cases (REDACTED) worldwide. According to GLOBOCAN, REDACTED% of new breast cancer cases in the Asia Pacific were registered in 2020.
Regulatory approvals that delay product marketing can adversely impact manufacturer revenues. Similarly, a delay in post-approval of a drug product for another therapeutic indication increases clinical trial costs and potentially affects the labeling and approval status of currently marketed products.
Table of Contents
Chapter 1 Introduction
Introduction
Study Goals and Objectives
Reasons for Doing the Study
Intended Audience
Scope and Format
Methodology
Market Estimates
Information Sources
Geographical Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
Homologous Recombination (HR)
Targets for Cancer Therapy
Chapter 4 Impact of COVID-19 Pandemic
Chapter 5 Market Dynamics
Market Drivers
Increasing Incidences of Chronic Diseases
Growing Aging Population
Advancements in Manufacturing Technologies
Market Restraints
Price Controls
Entry of Biosimilars
Opportunities
Untapped Potential in Emerging Markets
Chapter 6 Market Breakdown by Product Type
Human Protein Replacements
Market Size and Forecast
Therapeutic Agents for Human Diseases
Market Size and Forecast
Vaccines
Types of Vaccines
Market Size and Forecast
Chapter 7 Market Breakdown by End User
Biotechnology and Pharmaceutical Industry
Market Size and Forecast
Research Laboratories and Academic Institutes
Market Size and Forecast
Chapter 8 Market Breakdown by Region
Global Market by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 9 Competitive Landscape
Overview
Chapter 10 Company Profiles
ABBVIE INC.
ALEXION PHARMACEUTICALS
AMGEN INC.
ELI LILLY
MERCK & CO. INC.
SANOFI S.A.
TAKEDA PHARMACEUTICAL CO LTD.
List of Tables
Summary Table : Global Market for Human Recombinant DNA, by Region, Through 2027
Table 1 : Estimated World Population and Annual Growth, by Selected Age Group, Through 2030
Table 2 : Cancer Statistics Across Major Asian Countries, by Cancer Site/Type, 2020
Table 3 : Global Human Recombinant DNA Market, by Product Type, Through 2027
Table 4 : Global Market for Human Protein Replacements, by Region, Through 2027
Table 5 : Global Market for Therapeutic Agents for Human Diseases, by Region, Through 2027
Table 6 : Vaccine Types
Table 7 : Global Market for Vaccines, by Region, Through 2027
Table 8 : Global Market for Human Recombinant DNA, by End User, Through 2027
Table 9 : Global Market for Human Recombinant DNA in the Biotechnology and Pharmaceutical Industry, by Region, Through 2027
Table 10 : Global Market for Human Recombinant DNA in Research Laboratories and Academic Institutes, by Region, Through 2027
Table 11 : Global Market for Human Recombinant DNA, by Region, Through 2027
Table 12 : North American Market for Human Recombinant DNA, by Product Type Through 2027
Table 13 : North American Market for Human Recombinant DNA, by End User, Through 2027
Table 14 : North American Market for Human Recombinant DNA, by Country, Through 2027
Table 15 : European Market for Human Recombinant DNA, by Product Type, Through 2027
Table 16 : European Human Recombinant DNA Market, by End User, Through 2027
Table 17 : European Market for Human Recombinant DNA, by Country, Through 2027
Table 18 : Asia-Pacific Market for Human Recombinant DNA, by Product Type, Through 2027
Table 19 : Asia-Pacific Human Recombinant DNA Market, by End User, Through 2027
Table 20 : Asia-Pacific Market for Human Recombinant DNA, by Country, Through 2027
Table 21 : Japan: Total Number of New Cancer Cases in Both Genders, 2020
Table 22 : RoW Market for Human Recombinant DNA, by Product Type, Through 2027
Table 23 : RoW Market for Human Recombinant DNA, by End User, Through 2027
Table 24 : Leading Market Players in the Human Recombinant DNA Market Ecosystem
Table 25 : AbbVie Inc.: Business Segments
Table 26 : AbbVie Inc.: Financial Performance, Through 2020
Table 27 : Amgen: Financial Performance, Through 2020
Table 28 : Eli Lilly: Business Segments
Table 29 : Eli Lilly: Financial Performance, 2018-2020
Table 30 : Sanofi: Business Segments
Table 31 : Sanofi: Financial Performance, 2018-2020
List of Figures
Summary Figure A : Global Market for Human Recombinant DNA, by Region, 2020-2027
Summary Figure B : Global Market Shares of Human Recombinant DNA, by Region, 2021
Figure 1 : Global Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 2 : Global Market for Human Recombinant DNA, by Product Type, 2020-2027
Figure 3 : Global Market for Human Protein Replacements, 2020-2027
Figure 4 : Global Market for Therapeutic Agents for Human Diseases, 2020-2027
Figure 5 : Evolution of Vaccine Technologies
Figure 6 : Global Market for Vaccines, 2020-2027
Figure 7 : Global Market Shares of Human Recombinant DNA, by End User, 2021
Figure 8 : Global Market for Human Recombinant DNA, by End User, 2020-2027
Figure 9 : Global Market for Human Recombinant DNA in the Biotechnology and Pharmaceutical Industry, 2020-2027
Figure 10 : Global Market for Human Recombinant DNA in Research Laboratories and Academic Institutes, 2020-2027
Figure 11 : Global Market Shares of Human Recombinant DNA, by Region, 2021
Figure 12 : North American Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 13 : North American Market Shares of Human Recombinant DNA, by End User, 2021
Figure 14 : North American Market Shares of Human Recombinant DNA, by Country, 2021
Figure 15 : U.S. Market for Human Recombinant DNA, 2020-2027
Figure 16 : Canadian Market for Human Recombinant DNA, 2020-2027
Figure 17 : European Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 18 : European Human Recombinant DNA Market, Market Shares, by End User, 2021
Figure 19 : European Market Shares of Human Recombinant DNA, by Country, 2021
Figure 20 : Geriatric Population in Germany, 2000-2030
Figure 21 : German Market for Human Recombinant DNA, 2020-2027
Figure 22 : U.K. Market for Human Recombinant DNA, 2020-2027
Figure 23 : French Market for Human Recombinant DNA, 2020-2027
Figure 24 : Italian Market for Human Recombinant DNA, 2020-2027
Figure 25 : Spanish Market for Human Recombinant DNA, 2020-2027
Figure 26 : Rest of Europe Market for Human Recombinant DNA, 2020-2027
Figure 27 : Asia-Pacific Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 28 : Asia-Pacific Human Recombinant DNA Market, Market Shares, by End User, 2021
Figure 29 : Asia-Pacific Market Shares of Human Recombinant DNA, by Country, 2021
Figure 30 : New Cancer Cases in China, 2020
Figure 31 : Distribution of New Cancer Cases in China, 2020
Figure 32 : Chinese Market for Human Recombinant DNA, 2020-2027
Figure 33 : Japanese Market for Human Recombinant DNA, 2020-2027
Figure 34 : Indian Market for Human Recombinant DNA, 2020-2027
Figure 35 : Rest of Asia-Pacific Market for Human Recombinant DNA, 2020-2027
Figure 36 : New Cancer Cases in Africa, 2020
Figure 37 : RoW Market Shares of Human Recombinant DNA, by Product Type, 2021
Figure 38 : RoW Market Shares of Human Recombinant DNA, by End User, 2021
Figure 39 : AbbVie Inc.: Net Revenue, by Business Segment, 2020
Figure 40 : AbbVie Inc.: Net Revenue, by Region, 2020
Figure 41 : Amgen: Total Sales, by Product, 2020
Figure 42 : Amgen: Total Revenue, by Region, 2020
Figure 43 : Eli Lilly: Total Sales, by Product Segment, 2020
Figure 44 : Eli Lilly: Total Revenue, by Region, 2020
Figure 45 : Sanofi: Net Sales, by Business Segment, 2020
Figure 46 : Sanofi: Net Sales, by Region, 2020
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security